La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Clearside Biomedical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Clearside Biomedical..

Clearside Biomedical (NASDAQ:CLSD) Azioni, Catena delle Opzioni

CLEARSIDE BIOMEDICAL INC

Clearside Biomedical

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical Inc

WIIM

ETON

Eton Pharmaceuticals shares are trading higher after the company announced the FDA has accepted its new drug application for ET-600.

Barclays analyst Terry Ma maintains American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) with a Equal-Weight and raises the price target from $249 to $297.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on American Express, Raises Price Target to $297

Shares of Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) are moving higher Tuesday amid a complex mix of news involving potential U.S. export controls and newly announced tariffs on<a href="https://www.benzinga.com/markets/asia/25/07/46266218/us-plans-to-restrict-ai-chip-exports-to-malaysia-thailand-to-curb-diversion-to-china"> key Asian trading partners.</a>
What To Know: The Us Government is reportedly weighing restrictions on exports of AI chips to Malaysia and Thailand, a move aimed at blocking indirect access to advanced processors by China. Nvidia, a major supplier of AI chips, is expected to be affected by the draft rule from the Commerce Department, which targets countries seen as potential backdoor routes for Chinese companies. The rule is not final and could still be modified, but it signals a sharper stance on technology exports to Southeast Asia.
In a related development, President Donald Trump announced sweeping new tariffs as part of his renewed trade agenda, targeting imports from several nations including U.S. allies Japan and South Korea. A 25% tariff will apply to all goods from those two countries starting Aug. 1, unless trade negotiations succeed in reaching a resolution. Additional tariffs ranging from 25% to 40% were also introduced for countries like Malaysia, Thailand and others, according to Reuters.
Despite the headwinds for chipmakers tied to international sales and supply chains, AMD's stock held firm and rose, possibly reflecting investor confidence in the company's domestic positioning and product roadmap. It's also possible that some traders viewed the stock as relatively insulated from the immediate impact of export controls focused on Nvidia's high-end AI products.
AMD Price Action: Advanced Micro devices shares were up 2.72% at $138.47 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46296421/goldman-sachs-raises-sp500-forecast-6900">S&amp;P 500 Near 7,000? Inside Goldman&#8217;s New Gravity-Defying Forecast</a></li>
</ul>
Image Via Shutterstock.

Movers

AMD Stock Moves Higher Despite U.S. Chip Export Crackdown, Trump Tariff Escalation

Barclays analyst Terry Ma maintains Bread Finl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>) with a Underweight and raises the price target from $45 to $52.

Barclays Maintains Underweight on Bread Finl Hldgs, Raises Price Target to $52

ARWR

Arrowhead Pharmaceuticals shares are trading higher after the company announced it has dosed the first patient for its YOSEMITE Phase 3 trial of RNAi-based Zodasiran.

Barclays analyst Terry Ma maintains SoFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) with a Equal-Weight and raises the price target from $12 to $18.

SOFI

Barclays Maintains Equal-Weight on SoFi Technologies, Raises Price Target to $18

Barclays analyst Terry Ma maintains Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) with a Overweight and raises the price target from $62 to $81.

Barclays Maintains Overweight on Synchrony Financial, Raises Price Target to $81

MRNA

Moderna shares are trading higher after the company announced it will sue RFK Jr over what they deem to be unlawful COVID-19 vaccine rollbacks.

Barclays analyst Jared Shaw maintains Associated Banc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASB#NYSE">ASB</a>) with a Equal-Weight and raises the price target from $25 to $28.

Barclays Maintains Equal-Weight on Associated Banc, Raises Price Target to $28

SLNH

Soluna Holdings shares are trading higher after the company announced a 30 MW expansion with a bitcoin miner at its Dorothy 2 site.

Barclays analyst Jared Shaw maintains Banc of California (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BANC#NYSE">BANC</a>) with a Overweight and raises the price target from $18 to $19.

BANC

Barclays Maintains Overweight on Banc of California, Raises Price Target to $19

Barclays analyst Jared Shaw maintains Bank of Hawaii (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOH#NYSE">BOH</a>) with a Underweight and raises the price target from $67 to $68.

Barclays Maintains Underweight on Bank of Hawaii, Raises Price Target to $68

Barclays analyst Jared Shaw maintains BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) with a Equal-Weight and raises the price target from $38 to $41.

Barclays Maintains Equal-Weight on BankUnited, Raises Price Target to $41

U.S. stocks were little changed on Tuesday as investors stayed cautious following a series of letters from the White House to major trading partners, <a href="https://www.benzinga.com/topic/tariffs">outlining sweeping new tariffs. </a>
The real market action unfolded in commodities, with copper surging 10% after President Donald Trump announced a 50% tariff on copper imports starting today.
The industrial metal jumped to $5.52 per pound, hitting a new all-time high and marking its biggest one-day gain since October 2008.
During a Cabinet meeting, Trump stated: "Some letters are at a 60%, 70% rate.&#8221; He said to be announcing new tariff measures on pharmaceuticals — possibly a 200% tariff.
He added that trade relations with China have been "very fair" recently, noting a strong working relationship.
While Trump reiterated openness to trade negotiations, he emphasized that the U.S. will not extend the August deadline for reciprocal tariffs to take effect.
Commenting on the European Union, Trump said: "The EU has been speaking to us. President von der Leyen has been very nice lately, but they've treated us badly until recently. We're probably two days away from sending the EU letter. A letter is a deal."
At 1:40 p.m. ET, the S&amp;P 500 was flat at 6,220, the Nasdaq 100 gained 0.1% to 22,710, while small caps led the way with the Russell 2000 rising 0.9%.
Energy stocks outperformed as oil prices climbed 1.4% for a second straight session, topping $68 — a two-week high.
Treasury yields also moved higher, with the 10-year rising five basis points to 4.43% and the 30-year yield climbing to 4.96%.
The U.S. dollar remained steady, while gold fell 0.8% to $3,308 per ounce. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) traded around $109,125.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>% change</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,233.89</td>
<td>0.9%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>22,710.77</td>
<td>0.1%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,229.74</td>
<td>0.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,254.05</td>
<td>-0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 1:45 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) flattened at $570.48.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.3% lower to $442.54.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;eased 0.1% to $533.50.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.9% to $221.73.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 2.8%; the Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.3%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
<ul class="wp-block-list">
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) dropped 12%, while Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) fell 4.5% and First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) declined 6% after President Trump signed an order slashing tax credits for wind and solar energy.</li>
<li>Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) jumped 4.4%, benefiting from a sharp spike in copper prices following the newly announced tariffs.</li>
<li>Fair Isaac Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) sank 15% after Bill Pulte, director of the Federal Housing Finance Agency, announced Fannie Mae and Freddie Mac will now allow lenders to adopt the VantageScore 4.0 credit scoring model.</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) rallied 7.5% after Citigroup raised its price target on the stock from $21 to $24.</li>
<li>JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) declined 3.5% — its worst session since April — after HSBC downgraded the bank from Hold to Reduce and lifted its price target from $237 to $259.</li>
<li>Datadog Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) fell 4.3% to $145.81 after Guggenheim downgraded the stock from Neutral to Sell, setting a price target of $105.</li>
<li>Devon Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) surged 7.4% after JPMorgan increased its price target from $40 to $42 while maintaining a Neutral rating.</li>
<li>Other oil and gas majors advanced amid rising crude prices: Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) <a href="https://www.benzinga.com/etfs/sector-etfs/25/07/46304047/energy-etfs-in-focus-after-exxon-flags-1-5-billion-profit-hit">rose</a> 2.8%, Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) gained 3.5%, and ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) climbed 4.3%. 


</li>
</ul>
Read Now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46296421/goldman-sachs-raises-sp500-forecast-6900">S&amp;P 500 Near 7,000? Inside Goldman&#8217;s New Gravity-Defying Forecast</a></li>
</ul>
Photo: TimBrew via Shutterstock

Equities

Government

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Commodities

Global

Econ #s

Economics

Trading Ideas

ETFs

$BTC

DDOG

SPDR Dow Jones Industrial Average ETF Trust

ENPH

FICO

FSLR

INTC

Copper Rallies To Record Highs After Trump's 50% Tariff Bombshell: What's Moving Markets Tuesday?

Barclays analyst Jared Shaw maintains BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) with a Equal-Weight and raises the price target from $110 to $115.

BOKF

Barclays Maintains Equal-Weight on BOK Financial, Raises Price Target to $115

Exxon Mobil shares are trading higher after Piper Sandler raised its price target on the stock from $131 to $134 and maintained an Overweight rating.

Barclays analyst Jared Shaw maintains Cadence Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADE#NYSE">CADE</a>) with a Overweight and raises the price target from $38 to $41.

CADE

Barclays Maintains Overweight on Cadence Bank, Raises Price Target to $41

Freeport-McMoRan shares are trading higher after Citigroup raised its price target on the stock from $44 to $48.

Barclays analyst Jared Shaw maintains Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) with a Equal-Weight and lowers the price target from $32 to $27.

COLB

Barclays Maintains Equal-Weight on Columbia Banking System, Lowers Price Target to $27

SHEL

BP and Shell shares are trading higher after the companies announced deals to study the redevelopment of three oilfields in Libya.

Press Releases

Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD  and Suprachoroidal Delivery Platform Highlighted at the  2025 Wet AMD & Diabetic Eye Disease Summit

Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Earnings

Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Health Care

Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

Comments

Clearside Biomedical

Clearside Biomedical (CLSD) Opzioni

Clearside Biomedical (NASDAQ:CLSD) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO